Blue Line Capital
ABBV icon

Blue Line Capital’s AbbVie ABBV Stock Holding History

Blue Line Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.03M Buy
7,773
+855
+12% +$219K 1.58% 21
2026
Q2 		$1.74M Buy
6,918
+623
+10% +$134K 1.45% 20
2026
Q1 		$1.37M Buy
6,295
+543
+9% +$120K 1.55% 29
2025
Q4 		$1.31M Buy
+5,752
New +$1.31M 1.55% 19

Other funds holding ABBV

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Blue Line Capital's ABBV Position: Q3 2026 in Review

Blue Line Capital increased its AbbVie (ABBV) stake by 12% in Q3 2026, buying an estimated $219K and bringing the position to 7,773 shares worth $2.03M. The position accounts for 1.58% of the portfolio, ranked #21.

Blue Line Capital first reported a position in ABBV in Q4 2025 and has held it in 4 quarters since. 3,255 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Blue Line Capital held 7,773 shares of AbbVie worth $2.03M as of Q3 2026.
  • Blue Line Capital bought 855 AbbVie shares in Q3 2026, an estimated $219K.
  • AbbVie made up 1.58% of Blue Line Capital's portfolio in Q3 2026, its #21 holding.
  • Blue Line Capital first reported a position in AbbVie in Q4 2025 and has held it in 4 quarters since.
  • 3,255 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Blue Line Capital's 13F filing for Q3 2026, filed 4 Nov 2026.